DUBLINO–(BUSINESS WIRE)–Horizon Therapeutics (Nasdaq: HZNP) ha annunciato l’approvazione da parte della Commissione europea (CE) di inebilizumab come monoterapia per il trattamento di pazienti adulti con disturbo dello spettro della neuromielite otti…
Author: Business Wire
Europäische Kommission erteilt UPLIZNA® (Inebilizumab) die Zulassung zur Behandlung von Erwachsenen mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) gab heute bekannt, dass die Europäische Kommission die Zulassung für UPLIZNA® (Inebilizumab) als Monotherapie zur Behandlung erwachsener Patienten mit Neuromyelitis-optica-Spektrum-Erkran…
Horizon Therapeutics plc reçoit l’approbation de la Commission européenne (CE) pour UPLIZNA® (inébilizumab) dans le traitement des adultes atteints de troubles du spectre de la neuromyélite optique (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq : HZNP) a annoncé aujourd’hui l’approbation par la Commission européenne (CE) d’UPLIZNA® (inébilizumab) en monothérapie pour le traitement des patients adultes atteints de troubles du spectre de…
Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced the European Commission (EC) approval of UPLIZNA® (inebilizumab) as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who…
Eyevensys fera des présentations lors de la conférence annuelle 2022 de l'Association for Research in Vision and Ophthalmology (ARVO)
PARIS & CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–Eyevensys, une société privée de biotechnologie en phase clinique qui développe des thérapies géniques non virales pour les maladies oculaires, annonce que la société présentera des données préclinique…
Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eyevensys to present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2…
Aldeyra Therapeutics Announces Chief Financial Officer Transition
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities. Mr. Reed will continue to…
Ora Unveils Groundbreaking Ophthalmic Research Technologies at ARVO 2022
BOSTON–(BUSINESS WIRE)– #ARVO2022–Ora serves industry innovators by de-risking and accelerating development programs to demonstrate the efficacy of novel therapies through data-driven study design, global execution, and validated technologies that d…
Tesseract Health Appoints Dr. Michael McConnell as Head of Cardiovascular and Digital Health
GUILFORD, Conn.–(BUSINESS WIRE)–Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract’s …
Global Disposable Contact Lenses Market (2022 to 2027) – Shift to Premium & Cosmetic Contact Lenses Presents Opportunities – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Disposable Contact Lenses Market – Global Outlook & Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. This study considers a detailed scenario of the present disposable contact lenses mark…
Alcon Announces Results of 2022 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2022 Annual General Meeting
Alcon Announces Results of 2022 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Announces Results of 2022 Annual General Meeting
Worldwide Myopia and Presbyopia Treatment Industry to 2030 – Featuring AbbVie, Carl Zeiss and Nidek Among Others – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Myopia and Presbyopia Treatment Market Share, Size, Trends, Industry Analysis Report, By Myopia Treatment Type, By Presbyopia Treatment Type; By Region; Segment Forecast, 2022 – 2030” report has been added to ResearchAndMa…
Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting
SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)–Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, today announced that it will present new sc…
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to A…
EyeSouth Partners Affiliates with Center for Sight of Northwest Florida, Representing the Network’s 30th Affiliation and Seventh in Florida
ATLANTA–(BUSINESS WIRE)–EyeSouth Partners (“EyeSouth” or the “Company”) is pleased to announce that it has completed an affiliation with Center for Sight of Northwest Florida. The affiliation represents EyeSouth’s seventh in the state of Florida and …
Global OTC Artificial Tears Market Report 2022: Breakdown by Solution, Ointment, Emulsion, Gel, Spray, Solution, Suspensions – Forecast to 2027 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “OTC Artificial Tears Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The global OTC artificial tears market reached a val…
Iveric Bio to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
PARSIPPANY, N.J.–(BUSINESS WIRE)–Iveric Bio will participate in a fireside chat at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on Thursday, April 28, 2022.
Ocular Therapeutix™ to Report First Quarter 2022 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that i…